Similar articles

• Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis.

  Foroni L, Harrison CJ, Hoffbrand AV, Potter MN. Foroni L, et al. Br J Haematol. 1999 Apr;105(1):7-24. Br J Haematol. 1999. PMID: 10366253 Review. No abstract available.
• [Immunophenotyping in acute leukemia: detection of minimal residual disease].

  Pálóczi K, Nahajevszky S, Jakab K, Regéczy N, Gopcsa L, László E, Földi J. Pálóczi K, et al. Orv Hetil. 2000 Nov 12;141(46):2487-92. Orv Hetil. 2000. PMID: 11126681 Hungarian.
• [Minimal residual disease in childhood acute leukemias].

  Pawińska K, Balwierz W, Baran J. Pawińska K, et al. Przegl Lek. 2006;63(1):41-3. Przegl Lek. 2006. PMID: 16892899 Review. Polish.
• Molecular measurement of minimal residual disease in Philadelphia-positive acute lymphoblastic leukaemia.

  Radich JP. Radich JP. Best Pract Res Clin Haematol. 2002 Mar;15(1):91-103. doi: 10.1053/beha.2002.0187. Best Pract Res Clin Haematol. 2002. PMID: 11987918 Review.
• CDKN2 deletions have no prognostic value in childhood precursor-B acute lymphoblastic leukaemia.

  van Zutven LJ, van Drunen E, de Bont JM, Wattel MM, Den Boer ML, Pieters R, Hagemeijer A, Slater RM, Beverloo HB. van Zutven LJ, et al. Leukemia. 2005 Jul;19(7):1281-4. doi: 10.1038/sj.leu.2403769. Leukemia. 2005. PMID: 15843818 No abstract available.